Puretech Health Stock Price, News & Analysis

Vedanta Biosciences announced results from a Phase 1 study of VE202, a 16-strain live biotherapeutic product for inflammatory bowel disease (IBD), presented at the International Human Microbiome Consortium Congress 2021. The study showed VE202 was safe, well-tolerated, and led to durable colonization in healthy volunteers. Vedanta plans to advance VE202 to a Phase 2 trial for ulcerative colitis, funded partially by a $25 million investment from Pfizer. IBD affects approximately 3 million people in the U.S., highlighting the need for innovative treatments.

PureTech Health plc (Nasdaq: PRTC) expresses optimism following its Founded Entity, Karuna, announcing results from a Phase 1b trial of KarXT (xanomeline-trospium) in healthy elderly volunteers. The trial demonstrated that KarXT could be administered at therapeutic doses with a favorable safety and tolerability profile. Karuna plans to launch a Phase 2 trial targeting dementia-related psychosis in the first half of 2022. The majority of participants tolerated doses between 150-200 mg. PureTech holds an 8.2% stake in Karuna and is set to receive royalty payments from future net sales.

PureTech Health (Nasdaq: PRTC) has acquired the remaining 22% of shares in Alivio Therapeutics, enhancing its pipeline targeting inflammatory disorders like inflammatory bowel disease (IBD). This acquisition integrates Alivio’s technology into PureTech’s Wholly Owned Pipeline, including LYT-500, an oral treatment for IBD. This strategic move is set to be funded through partnerships and grants, aligning with PureTech's financial plan extending into Q1 2025. The transaction consists of a cash payment and future milestone payments, which are categorized as smaller transactions under listing rules.

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC) took place on May 27, 2021, with all proposed resolutions passing successfully. Key results include:

• Approval of the Annual Report for 2020: 100% votes in favor.
• Directors’ Remuneration Report: 89.74% approval.
• Directors’ Remuneration Policy: 83.90% approval.
• Election of directors Dr. Raju Kucherlapati and Dame Marjorie Scardino received 98.73% and 98.54% approval, respectively.
• Reappointment of KPMG LLP as Auditors: 99.90% approval.

These results reflect strong shareholder support for the Company's governance and financial reporting.

PureTech Health plc (Nasdaq: PRTC) noted a significant development from its Founded Entity Gelesis, which presented findings at the AACE 2021 Annual Meeting. A post-hoc analysis indicated that Plenity treatment led to a decline in the NALFD fibrosis score, a marker for liver fibrosis, compared to the placebo group. This analysis supports further trials of Plenity for metabolic-related liver diseases. Gelesis aims to enroll the first patient for a clinical study of its therapeutic candidate in NASH/NAFLD by the year's end.

PureTech Health (Nasdaq: PRTC) announced that Akili Interactive has raised $160 million through a combination of equity and debt financing. The financing includes a $110 million Series D equity round led by Neuberger Berman Funds, with participation from new and existing investors. This round brings Akili’s total equity funding to $230 million. The funds will enhance commercialization efforts for Akili's flagship product, EndeavorRx™, the first prescription video game treatment, and further support the development of digital therapeutics for cognitive disorders.

PureTech Health (Nasdaq: PRTC) announced that Daphne Zohar, Founder and CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2nd at 9:00 AM EST. The event will be webstreamed for broader access. PureTech is dedicated to developing differentiated medicines for severe diseases and boasts a pipeline of 26 therapeutic candidates. Their expertise focuses on the BIG Axis, integrating brain, immune, and gut biology for innovative treatment options.

PureTech Health (Nasdaq: PRTC) announced the formation of a Clinical Advisory Board to advance LYT-100 (deupirfenidone) for idiopathic pulmonary fibrosis (IPF) and related lung diseases. The board consists of renowned experts in fibrosing lung diseases who will assist in the development of LYT-100, which aims to improve patient compliance due to its favorable safety profile compared to existing treatments. With around 200,000 patients affected by IPF in the U.S., this initiative addresses a significant medical need as current options have tolerability issues.

PureTech Health (Nasdaq: PRTC) announced new preclinical research published in Nature that suggests enhancing meningeal lymphatic drainage could significantly improve clinical outcomes for Alzheimer’s disease. The study links impaired lymphatic function to microglia activation issues, affecting treatment efficacy. This research potentially paves the way for new therapeutic approaches, working alongside existing immunotherapies targeting amyloid beta. PureTech holds an exclusive license for this intellectual property and is advancing this research within its meningeal lymphatics program.